GuangZhou Cellgenes Biotechnology
CompanyChina
GuangZhou Cellgenes Biotechnology develops one asset, in phase 1 (CG-BM1 in sarcopenia). Mostly cell therapy; based in China.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 1
- Signal
Pipeline
1Allogeneic human bone marrow mesenchymal stem cell therapy intended to treat sarcopenia.
Phase 1, Cell therapy, sarcopenia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Signals1
- Similar companies6